FIELD: medicine.
SUBSTANCE: group of inventions refers to cancer treatment in a patient. That is ensured by administering an effective amount of a compound which inhibits ATR protein kinase to a patient suffering cancer; and administering to the patient an effective amount of a compound which inhibits Chk1 protein kinase; wherein the compound which inhibits ATR is
VE-822
or a pharmaceutically acceptable salt thereof. Group of inventions also relates to a method of stimulating cell death of cancer cells in a patient, use of a compound which inhibits ATR protein kinase, when preparing a drug preparation for treating cancer in a patient and using the compound, which inhibits ATR protein kinase, in the manufacture of a medicament for promoting cancer cell death in a patient.
EFFECT: group of inventions provides a synergetic effect in treating cancer despite target protein kinases on the same biological pathway.
77 cl, 10 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS | 2016 |
|
RU2768621C1 |
| TREATING PANCREATIC CANCER AND NON-SMALL CELL LUNG CANCER WITH ATR INHIBITORS | 2012 |
|
RU2648507C2 |
| COMBINATION OF CHEKPOINT-KINASE 1 INHIBITORS AND WEE 1 KINASE INHIBITORS | 2011 |
|
RU2627841C2 |
| METHODS FOR TREATMENT OF MALIGNANT TUMORS, USING ATR INHIBITOR | 2018 |
|
RU2813966C2 |
| BENZIMIDAZOLES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2415853C2 |
| INTERMEDIATE CHEMICAL COMPOUNDS AND METHODS FOR PRODUCING COMPOUNDS | 2013 |
|
RU2635359C2 |
| TRIAZOLES USED AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2393155C2 |
| METHODS BASED ON DETECTING RAD51 FOCI IN TUMOUR CELLS | 2018 |
|
RU2825699C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF MALIGNANT TUMOUR | 2013 |
|
RU2660349C2 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
